HIV vaccine research at Gates Foundation: mRNA and beyond

In the next few years, scientists around the globe are making plans to achieve effective immune responses considered to be relevant for developing an efficacious prophylactic HIV vaccine. What role will mRNA technology play in this mission? Charlotte Barker, Commissioning Editor of Vaccine Insights, speaks with Pervin Anklesaria, Deputy Director, HIV Vaccines & Biologics at the Gates Foundation, to find out. Additionally, Anklesaria provides an update on the Gates Foundation’s research priorities in HIV and shares insights on successful collaboration.

Please enter your email to access content Read now